Palivizumab

帕利珠单抗

Report date: 2024/03/14 15:19:50

Base Information

Drug NamePalivizumab
Drug Alias Namepalivizumabum帕利韦珠单抗SynagisABT-315MEDI-493
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionRespiratory syncytial virus F protein inhibitors
TargetsRespiratory syncytial virus F protein
Therapy Area/IndicationsInfant, Premature, DiseasesHeart Defects, CongenitalPremature Birth +[6] 
Global Approved IndicationsRespiratory Syncytial Virus Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1998/06/19
Country/TerritoryUnited StatesRussian FederationQatar +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaIND
Originator CompaniesAbbvie IncMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesAbbott LaboratoriesSwedish Orphan Biovitrum Ab (Publ)Astrazeneca Ab +[5] 
Inactive CompaniesHamad Medical CorporationMedimmune Llc
Active IndicationsRespiratory Syncytial Virus Infections
Inactive IndicationsInfant, Premature, DiseasesHeart Defects, CongenitalPremature Birth +[5] 

Other Information

ATC CodeJ06BB16J06BD01
Related LinksWikipediaDrugBankKEGG